Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioMS Medical has received approval from the Swedish Medical Products Agency to expand its phase II/III clinical trial of its multiple sclerosis drug, MBP8298, to patients in Sweden.
Subscribe to our email newsletter
The trial which tests the effects of the drug in patients with secondary progressive multiple sclerosis (SPMS) is currently enrolling patients in Canada and the UK. Up to 553 patients will be administered either MBP8298 or placebo intravenously every six months for a period of two years.
“We are very pleased to expand this trial into Sweden. Sweden has a higher prevalence of MS, similar to that of the UK, Canada and the northern US and as a result, the country conducts leading edge research on the disease. This is an important opportunity for us to conduct our trial in another population where clinicians have extensive experience with MS and where there is a large unmet need for an effective treatment,” said Kevin Giese, president of BioMS Medical.